These findings suggest that drugs such as oxiglutathione, thymopentin, deferoxamine mesylate, dermorphin, pralmorelin acetate, tetragastrin, ritonavir, leucovorin calcium pentahydrate, and pralatrexate may have potential antitumor effects on HCC by targeting LRRC41, which opens up new possibilities for repurposing existing drugs for the treatment of HCC. Here, LRRC41 is linked to hepatocellular carcinoma.